The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of sorafenib in combination with gemcitabine and fluorouracil in metastatic renal-cell carcinoma: Preliminary result of a multicenter phase II study.
J. Guo
No relevant relationships to disclose
C. L. Cui
No relevant relationships to disclose
H. Chen
No relevant relationships to disclose
X. D. Xie
No relevant relationships to disclose
J. Chen
No relevant relationships to disclose
J. Liang
No relevant relationships to disclose
F. Li
No relevant relationships to disclose
T. S. Liu
No relevant relationships to disclose
Z. H. Chi
No relevant relationships to disclose
L. Si
No relevant relationships to disclose
X. N. Sheng
No relevant relationships to disclose
S. M. Li
No relevant relationships to disclose